Lilly’s Pegilodecakin Fails Pancreatic Cancer Test
Asset came from $1.6bn Armo buy
Executive Summary
The company's immunotherapy failed to improve survival of pancreatic patients compared to chemotherapy. Lilly will be hoping pegilodecakin has more success in NSCLC.
You may also be interested in...
Lilly Calls It Quits On Pegilodecakin As Loxo Team Reorganizes Cancer R&D
Revealing that the pegylated IL-10 therapy acquired in the Armo buyout two years ago has failed a pair of Phase II NSCLC trials, Lilly said it plans no further studies with the drug. Trulicity and Taltz led Lilly’s continuing growth story.
Lilly Taps Loxo Execs To Bring Back That Biotech Feeling
Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.
Lilly’s Diabetes Franchise Poised For A Shakeup As Conterno Steps Down
Lilly’s newer diabetes drugs are selling well, although Trulicity numbers disappointed analysts, and are among the firm’s growth-drivers. Longtime diabetes head Enrique Conterno will be succeeded by insider Mike Mason.